Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS636 monotherapy for relapsed or refractory primary mediastinal large B-cell lymphoma
ChiCTR2100044452Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of sudubrilimab, sponsored by Sun Yat-sen University Cancer Center. Started Jan 2021; status: recruiting.
02
Drugs
sudubrilimab
Beyond the preview
Go deeper on ChiCTR2100044452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044452.